Vazegepant

Unassigned

New Medicines

Chronic and episodic migraine - treatment

Information

New molecular entity
Biohaven Pharmaceuticals
Biohaven Pharmaceuticals

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Intranasal calcitonin gene-related peptide (CGRP) receptor antagonist
Migraine has an estimated global prevalence of 14.7% (~1 in 7 people) and is more common is women. It is estimated that ~ there are ~ 190,000 migraine attacks every day in the UK although migraine remains undiagnosed and undertreated in at least 50% of pts. [1]
Chronic and episodic migraine - treatment
Intranasal